PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC

Teripulimab 240mg, injection or Carrelizumab 200mg, injection, every 3 weeks.

Irinotecan: 200mg/m2, injection (For patients who are confirmed to be homozygous for UGT1A1\*6 or UGT1A1\*28 or UGT1A1\*6 and UGT1A1\*28 at the same time, the starting dose of CPT-11 is 150 mg/m2).

Capecitabine: 1600 mg/m2/d, oral, 2 weeks on and 1 week off.